HK1163119A1 - Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4 - Google Patents

Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4

Info

Publication number
HK1163119A1
HK1163119A1 HK12103380.8A HK12103380A HK1163119A1 HK 1163119 A1 HK1163119 A1 HK 1163119A1 HK 12103380 A HK12103380 A HK 12103380A HK 1163119 A1 HK1163119 A1 HK 1163119A1
Authority
HK
Hong Kong
Prior art keywords
cxcr4
treatment
cancer
antibodies
cxcr4 antibodies
Prior art date
Application number
HK12103380.8A
Other languages
English (en)
Chinese (zh)
Inventor
．克林格-阿穆
．格勒尼耶-科薩內爾
Original Assignee
皮埃爾法布雷醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 皮埃爾法布雷醫藥公司 filed Critical 皮埃爾法布雷醫藥公司
Publication of HK1163119A1 publication Critical patent/HK1163119A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
HK12103380.8A 2008-10-01 2012-04-05 Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4 HK1163119A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13677208P 2008-10-01 2008-10-01
EP08305631A EP2172485A1 (de) 2008-10-01 2008-10-01 Neuartige Anti-CXCR4-Antikörper und ihre Verwendung bei der Krebsbehandlung
US17374309P 2009-04-29 2009-04-29
PCT/EP2009/062787 WO2010037831A1 (en) 2008-10-01 2009-10-01 Anti cxcr4 antibodies and their use for the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1163119A1 true HK1163119A1 (en) 2012-09-07

Family

ID=40361774

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12103380.8A HK1163119A1 (en) 2008-10-01 2012-04-05 Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4

Country Status (29)

Country Link
US (4) US8557964B2 (de)
EP (2) EP2172485A1 (de)
JP (1) JP5723279B2 (de)
KR (1) KR101671039B1 (de)
CN (1) CN102209730B (de)
AR (1) AR073748A1 (de)
AU (1) AU2009299787B2 (de)
BR (1) BRPI0920531A2 (de)
CA (1) CA2738782C (de)
CL (1) CL2011000730A1 (de)
CY (1) CY1115572T1 (de)
DK (1) DK2342233T3 (de)
ES (1) ES2503732T3 (de)
GE (1) GEP20146084B (de)
HK (1) HK1163119A1 (de)
HR (1) HRP20140899T1 (de)
IL (1) IL212066A (de)
MA (1) MA32928B1 (de)
MX (1) MX2011003509A (de)
NZ (1) NZ592363A (de)
PL (1) PL2342233T3 (de)
PT (1) PT2342233E (de)
RS (1) RS53578B1 (de)
RU (1) RU2573897C2 (de)
SI (1) SI2342233T1 (de)
TW (1) TWI469792B (de)
UA (1) UA102867C2 (de)
WO (1) WO2010037831A1 (de)
ZA (1) ZA201102969B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246364A1 (de) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Antikörper gegen CXCR4 zur Behandlung von HIV
EP2371863A1 (de) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Menschlische Antikörper gegen CXCR4 zur Behandlung von Krebs
KR20140009174A (ko) * 2010-10-27 2014-01-22 피에르 파브르 메디카먼트 Hiv의 치료를 위한 항체들
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
EP3626739A1 (de) 2011-06-24 2020-03-25 Stephen D. Gillies Leichtkettige immunglobulinfusionsproteine und verfahren zur verwendung davon
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
AR087364A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
NL2010658C2 (en) * 2013-04-18 2014-10-21 Bosch Gmbh Robert Thermostat for a hvac.
MX371455B (es) * 2013-08-02 2020-01-28 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
CN113801895A (zh) 2013-09-23 2021-12-17 威尔逊沃夫制造公司 遗传修饰动物细胞的改进方法
TWI740824B (zh) * 2015-04-27 2021-10-01 法商皮爾法伯製藥公司 新穎的ｉｇｆ－１ｒ抗體及其用於癌症診斷之用途（一）
BR112017026189A2 (pt) 2015-06-12 2018-08-14 Bristol Myers Squibb Co tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
EP3374383A4 (de) * 2015-11-09 2019-05-15 The University Of British Columbia Amyloid-beta-epitope und antikörper dagegen
WO2017132202A1 (en) 2016-01-25 2017-08-03 Nant Holdings Ip, Llc Nk cells with altered cxcl12/cxcr4 signaling
WO2017203799A1 (ja) * 2016-05-25 2017-11-30 株式会社東芝 エネルギー管理装置、管理システム、消費電力監視方法及びプログラム
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
WO2018143938A1 (en) * 2017-01-31 2018-08-09 Msm Protein Technologies Inc. Anti-cxcr4 antibodies
WO2019175802A1 (en) 2018-03-13 2019-09-19 Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy
CN110804100A (zh) * 2019-11-01 2020-02-18 中国人民解放军陆军特色医学中心 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN112661845B (zh) * 2020-12-25 2022-06-21 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及其应用
CN112521500B (zh) * 2020-12-25 2022-06-24 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及应用
CN118255888A (zh) * 2023-08-31 2024-06-28 恺佧生物科技(上海)有限公司 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6949243B1 (en) * 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
WO2006086883A1 (en) * 2005-02-16 2006-08-24 Universite De Montreal Biosensors for monitoring receptor-mediated g-protein activation
WO2006089141A2 (en) * 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
AU2009246683A1 (en) * 2008-05-14 2009-11-19 Eli Lilly And Company Anti-CXCR4 antibodies

Also Published As

Publication number Publication date
EP2342233A1 (de) 2011-07-13
MX2011003509A (es) 2011-05-02
AU2009299787A1 (en) 2010-04-08
AR073748A1 (es) 2010-12-01
RU2011115559A (ru) 2012-11-10
JP5723279B2 (ja) 2015-05-27
AU2009299787B2 (en) 2015-06-18
JP2012504401A (ja) 2012-02-23
PT2342233E (pt) 2014-10-03
CL2011000730A1 (es) 2012-02-03
EP2342233B1 (de) 2014-06-25
TW201018483A (en) 2010-05-16
NZ592363A (en) 2012-08-31
IL212066A0 (en) 2011-06-30
HRP20140899T1 (hr) 2014-11-07
US20110294156A1 (en) 2011-12-01
US20110020218A1 (en) 2011-01-27
TWI469792B (zh) 2015-01-21
RU2573897C2 (ru) 2016-01-27
US8557964B2 (en) 2013-10-15
EP2172485A1 (de) 2010-04-07
AU2009299787A2 (en) 2011-06-02
SI2342233T1 (sl) 2014-10-30
CA2738782A1 (en) 2010-04-08
US20110287451A1 (en) 2011-11-24
KR20110081229A (ko) 2011-07-13
WO2010037831A1 (en) 2010-04-08
US9388248B2 (en) 2016-07-12
MA32928B1 (fr) 2012-01-02
CY1115572T1 (el) 2017-01-04
CA2738782C (en) 2017-11-28
ES2503732T3 (es) 2014-10-07
ZA201102969B (en) 2011-12-28
US20140050661A1 (en) 2014-02-20
KR101671039B1 (ko) 2016-11-01
CN102209730A (zh) 2011-10-05
CN102209730B (zh) 2014-11-05
BRPI0920531A2 (pt) 2021-02-23
DK2342233T3 (da) 2014-09-29
IL212066A (en) 2015-05-31
RS53578B1 (en) 2015-02-27
UA102867C2 (uk) 2013-08-27
GEP20146084B (en) 2014-05-13
PL2342233T3 (pl) 2014-11-28

Similar Documents

Publication Publication Date Title
HK1163119A1 (en) Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4
IL247183B (en) Secretory-apoptosis factors for the treatment of cancer and immune and autoimmune diseases
IL213070A0 (en) Methods for the treatment of infections and tumors
EP2277049A4 (de) Autoantikörper für den nachweis und die behandlung von krebs
PL2532364T3 (pl) Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi
EP2216344A4 (de) Diagnose und behandlung von krebs mit einem anti-gpr49-antikörper
HK1159498A1 (en) Methods and compositions for the treatment of cancer
EP2652506A4 (de) Verwendung von antikörpern gegen cxcl16 und cxcr6 zur behandlung bzw. zum nachweis von krebs
EP2652508A4 (de) Verwendung von anti-cxcl13- und anti-cxcr5-antikörpern zur behandlung oder zum nachweis von krebs
EP2340027A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs
HK1178910A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer cxcr4
GB0807018D0 (en) Antibodies and treatment
IL214349A0 (en) Compositions and methods for the treatment of cancer
EP2144887A4 (de) Darreichungsformen und verfahren zur behandlung von krebs
EP2437738A4 (de) Verfahren und zusammensetzungen zur krebsbehandlung
EP2150270A4 (de) Verfahren und zusammensetzungen zur krebsbehandlung
EP2377891A4 (de) Diagnose und behandlung von krebs mit anti-lgr7-antikörper
EP2420515A4 (de) Diagnose und behandlung von krebs mit anti-tmprss11e-antikörper
EP2331130A4 (de) Ige-antikörper zur behandlung von krebs
EP2361317A4 (de) Verwendung von eif3m zur diagnose und behandlung von krebs
EP2411031A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs
EP2123676A4 (de) Diagnose und behandlung von krebs unter verwendung von anti-prg-3-antikörpern
HK1209754A1 (en) Compounds and methods for the treatment of cancer
GB0700281D0 (en) Methods and Means for the Treatment of Cancer
IL211752A0 (en) Antibody combinations and use of same for treating cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191001